IL6R and cancer: Due to the capacity of Hyper-IL6, a fusion protein between IL6 and IL6Rα [87,88], to activate gp130 receptors independently of the presence of the ligand-binding IL6Rα subunit, these observations suggest that cancer-initiating cells may not always express sufficient IL6Rα subunits to respond to IL6.